CoronaVac + BNT162b2

This refers to a heterologous prime-boost COVID-19 vaccination regimen studied by the Institut Pasteur de Tunis in a single-blinded, randomized Phase III superiority trial. The regimen consists of an initial dose of CoronaVac (an inactivated SARS-CoV-2 vaccine developed by Sinovac) followed by a second dose of BNT162b2 (Comirnaty, an mRNA vaccine developed by Pfizer-BioNTech) administered approximately three weeks later. The trial compared this heterologous (mix-and-match) approach against a homologous regimen of two CoronaVac doses in COVID-19 vaccine-naïve adults. The study demonstrated that the heterologous CoronaVac/BNT162b2 regimen showed superior immunogenicity compared to the homologous CoronaVac/CoronaVac regimen, with a higher percentage of subjects achieving neutralizing antibodies. The trial was registered under NCT05668065 and TN2021-NAT-INS-70.

Other names

CoronaVac + BNT162b2-Institut Pasteur de Tunis-COVID-19CoronaVac/BNT162b2CoronaVac/Comirnatyheterologous CoronaVac/BNT162b2 regimen